Identification of Drivers from Cancer Genome Diversity in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most common cancers with a dismal outcome. The complicated molecular pathogenesis of HCC caused by tumor heterogeneity makes it difficult to identify druggable targets useful for treating HCC patients. One approach that has a potential for the improvemen...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2014-06-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/1422-0067/15/6/11142 |
id |
doaj-f8f16ae6edea46878577d114edfd1e46 |
---|---|
record_format |
Article |
spelling |
doaj-f8f16ae6edea46878577d114edfd1e462020-11-25T00:48:55ZengMDPI AGInternational Journal of Molecular Sciences1422-00672014-06-01156111421116010.3390/ijms150611142ijms150611142Identification of Drivers from Cancer Genome Diversity in Hepatocellular CarcinomaAtsushi Takai0Hien T. Dang1Xin W. Wang2Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USALaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USALaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USAHepatocellular carcinoma (HCC) is one of the most common cancers with a dismal outcome. The complicated molecular pathogenesis of HCC caused by tumor heterogeneity makes it difficult to identify druggable targets useful for treating HCC patients. One approach that has a potential for the improvement of patient prognosis is the identification of cancer driver genes that play a critical role in the development of HCC. Recent technological advances of high-throughput methods, such as gene expression profiles, DNA copy number alterations and somatic mutations, have expanded our understanding of the comprehensive genetic profiles of HCC. Integrative analysis of these omics profiles enables us to classify the molecular subgroups of HCC patients. As each subgroup classified according to genetic profiles has different clinical features, such as recurrence rate and prognosis, the tumor subclassification tools are useful in clinical practice. Furthermore, a global genetic analysis, including genome-wide RNAi functional screening, makes it possible to identify cancer vulnerable genes. Identification of common cancer driver genes in HCC leads to the development of an effective molecular target therapy.http://www.mdpi.com/1422-0067/15/6/11142hepatocellular carcinomatumor heterogeneitycancer driver gene |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Atsushi Takai Hien T. Dang Xin W. Wang |
spellingShingle |
Atsushi Takai Hien T. Dang Xin W. Wang Identification of Drivers from Cancer Genome Diversity in Hepatocellular Carcinoma International Journal of Molecular Sciences hepatocellular carcinoma tumor heterogeneity cancer driver gene |
author_facet |
Atsushi Takai Hien T. Dang Xin W. Wang |
author_sort |
Atsushi Takai |
title |
Identification of Drivers from Cancer Genome Diversity in Hepatocellular Carcinoma |
title_short |
Identification of Drivers from Cancer Genome Diversity in Hepatocellular Carcinoma |
title_full |
Identification of Drivers from Cancer Genome Diversity in Hepatocellular Carcinoma |
title_fullStr |
Identification of Drivers from Cancer Genome Diversity in Hepatocellular Carcinoma |
title_full_unstemmed |
Identification of Drivers from Cancer Genome Diversity in Hepatocellular Carcinoma |
title_sort |
identification of drivers from cancer genome diversity in hepatocellular carcinoma |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1422-0067 |
publishDate |
2014-06-01 |
description |
Hepatocellular carcinoma (HCC) is one of the most common cancers with a dismal outcome. The complicated molecular pathogenesis of HCC caused by tumor heterogeneity makes it difficult to identify druggable targets useful for treating HCC patients. One approach that has a potential for the improvement of patient prognosis is the identification of cancer driver genes that play a critical role in the development of HCC. Recent technological advances of high-throughput methods, such as gene expression profiles, DNA copy number alterations and somatic mutations, have expanded our understanding of the comprehensive genetic profiles of HCC. Integrative analysis of these omics profiles enables us to classify the molecular subgroups of HCC patients. As each subgroup classified according to genetic profiles has different clinical features, such as recurrence rate and prognosis, the tumor subclassification tools are useful in clinical practice. Furthermore, a global genetic analysis, including genome-wide RNAi functional screening, makes it possible to identify cancer vulnerable genes. Identification of common cancer driver genes in HCC leads to the development of an effective molecular target therapy. |
topic |
hepatocellular carcinoma tumor heterogeneity cancer driver gene |
url |
http://www.mdpi.com/1422-0067/15/6/11142 |
work_keys_str_mv |
AT atsushitakai identificationofdriversfromcancergenomediversityinhepatocellularcarcinoma AT hientdang identificationofdriversfromcancergenomediversityinhepatocellularcarcinoma AT xinwwang identificationofdriversfromcancergenomediversityinhepatocellularcarcinoma |
_version_ |
1725254152524660736 |